Clinical Trials Webinars

The challenge of running successful global trials is highly demanding and has become increasingly costly. Sourcing commercially available medications for these trials can be both complex and resource-intensive. This webinar will introduce innovative sourcing strategies for commercially available medications while assessing the pros and cons of the different options. The speaker will provide insight into key considerations when choosing the appropriate sourcing option(s) and discuss the value of migrating from a transactional approach to strategic sourcing.

The MRCT Center and Medable created a task-force to tackle the ethical and regulatory challenges of Decentralized Clinical Trials (DCTs). Join this webinar to learn about the tools and guidelines developed by Medable and MRCT for ethical review of DCTs. The webinar will cover topics like eConsent, recruitment and remote visits, privacy and security concerns, and issues related to devices used in DCTs.

CEO Amir Reichman will review Scinai’s 2023 accomplishments and discuss 2024 plans, including bringing Scinai’s anti-IL-17 VHH antibody (‘NanoAb’) innovative psoriasis treatment into clinical trials by the end of 2024.

In this groundbreaking webinar, discover the latest in retina therapy programs and clinical research to enhance success in ophthalmic trials with insights from industry experts. With over 250 individual therapies in development to address these challenging-to-treat conditions including inherited retina diseases, diabetic retinopathy and macular degeneration, the innovation within this space is likely unsurpassed by any other. Excitingly, many of these include novel mechanisms of action or gene therapies that show potential for different therapeutic impacts from current therapies on the market, such as treating conditions where there are no therapies with approved indications or targeting earlier-stage disease interventions.

Join us for a cutting-edge webinar delving into innovative clinical approaches and endpoints for new glaucoma treatments. Today, intraocular pressure (IOP) lowering therapies are currently the only proven neuroprotective therapies for glaucoma. While IOP therapies and devices are highly prevalent in use, unfortunately even with these treatments up to one in four patients still experience blindness in at least one eye. With disease progression still often significant despite the application of these therapies, clearly, this is an area of opportunity for new therapeutic entries. As companies explore new therapies to provide neuroprotection (preserving neuronal integrity) or even neuroenhancement (improving neuronal function), finding the right clinical approaches and endpoints to prove efficacy is of utmost importance. This webinar, featuring leading glaucoma expert and Ora Chief Medical Officer, Dr. Gustavo De Moraes, highlights ground-breaking designs and endpoints for new glaucoma therapies that help better measure therapeutic impact and even demonstrate IOP-independent neuroprotection. Hear an overview of the latest research in this field, understand considerations for programs including currently stated FDA opinions, and dive deeply into recent studies that show the viability of these novel endpoints to demonstrate efficacy for new glaucoma potential therapies. Ora Inc. is the only ophthalmic clinical trials company with a research and development (R&D) department focused on the evolution of clinical trials. As one of the top glaucoma experts in the world, Dr. De Moraes leads the Ora R&D team in exploring and developing new endpoints. He is excited to share with attendees the latest research shaping the future of glaucoma clinical trials, and to provide considerations for their therapeutic program to optimally capture the efficiency benefits for these challenging patients.

Clinical research often lacks sufficient evidence, leading to prescribing decisions in healthcare that are not evidence-based or supported by randomized, double-blind clinical trials. This webinar will discuss how combining a unified clinical trial data collection platform with intelligent automation can revolutionize drug development and why the current status quo is no longer sufficient.

Since 2017, the FDA’s Oncology Center of Excellence (OCE) has created more than 300 research and educational outreach projects and programs focused on advancing the design, analysis, and regulations surrounding oncology drug development. In this webinar, Worldwide Clinical Trials’ clinical research methodology and oncology strategy experts will present the OCE’s most imperative initiatives.

Discover a groundbreaking webinar delving into the future of dry eye clinical trial design and execution for emerging treatments. A highly prevalent multi-factorial disease affecting millions of patients, dry eye disease can still be a challenging condition to treat. This webinar will discuss ways to optimize dry eye clinical trial designs and execution.

Patient diversity and representation in clinical trials have become a priority for stakeholders across the industry and for regulatory authorities around the world. Join the featured speakers as they discuss some of the factors underpinning the lack of patient diversity in clinical trials, investigate the implications this has for patients, and discuss what we can do to design more patient-centric and diverse clinical trials.

Discover an informative webinar to unravel the complexity of the Clinical Trials Information System (CTIS) and explore the regulatory structure in Europe. Most importantly, let’s discuss whether all the latest changes in the regulatory landscape still position Europe as the number one destination for clinical trials.